Basit öğe kaydını göster

dc.contributor.authorKaradağ, Ömer
dc.contributor.authorSeyhoglu, Emrah
dc.contributor.authorUyaroğlu, Oğuz Abdullah
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorKilic, Levent
dc.contributor.authorAkdogan, Ali
dc.contributor.authorApras Bilgen, Sule
dc.contributor.authorErtenli, Ihsan
dc.contributor.authorKiraz, Sedat
dc.contributor.authorKalyoncu, Umut
dc.date.accessioned2021-03-15T12:44:42Z
dc.date.available2021-03-15T12:44:42Z
dc.date.issued2020-10-15
dc.identifier.citationSeyhoglu E, Uyaroğlu OA, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli I, Kiraz S, Kalyoncu U. QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. Clin Rheumatol. 2020 Oct 15. doi: 10.1007/s10067-020-05443-3. Epub ahead of print. PMID: 33057917.tr_TR
dc.identifier.urihttps://doi.org/10.1007/s10067-020-05443-3
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/33057917/
dc.identifier.urihttps://link.springer.com/article/10.1007/s10067-020-05443-3
dc.identifier.urihttp://hdl.handle.net/11655/23550
dc.description.abstractObjectives The Turkish population is vaccinated with Bacille Calmette-Guérin (BCG), and the BCG vaccination decreases the specificity of the tuberculin skin test (TST). The purpose of this study was to investigate the incidence of active tuberculosis (TBC) among rheumatic patients who were screened only with the QuantiFERON®-TB Gold In-Tube (QFT-GIT) test for latent TBC prior to biological treatment. Methods The Hacettepe University Biological Database (HUR-BIO) was used for latent TBC assessment. Consecutive patients were evaluated from July 2015 to October 2016 by a questionnaire that included the patients’ demographic characteristics, treatment history, and symptoms of active TBC. A total of 664 patients were interviewed by physicians. TBC statuses of the 671 non-interviewed patients were checked from the Turkish National Tuberculosis Registry records. Mean TBC incidence per year was calculated for anti-tumor necrosis factor-alpha (TNF-α) agents. Results A total of 1335 (58.2% female) patients with the mean age of 44.2 ± 12.9 years were included. Of the patients, 836 (62.6%) had spondyloarthropathy, 432 (32.4%) had rheumatoid arthritis, and 67 (5%) had other rheumatologic diseases. The total biological drug exposure was 2292 patient-years (2043 patient-years for anti-TNF-α, 249 patient-years for non-TNF-α inhibitors). Positive and indeterminate QFT-GIT results were found in 258 (19.3%) and 23 (1.7%) patients, respectively. The median follow-up time after the onset of biological agent was 19.4 months (IQR = 29.5). Pulmonary TBC was found in 3 (0.2%) of the 1335 patients. The annual incidence of TBC was 147/100,000 patient-years for all TNF-α inhibitors (249/100,000 and 123/100,000 patient-years for QFT-GIT-positive and negative patients, respectively). Conclusions TBC incidence increased by nearly seven times the Turkish national TBC incidence. The QFT-GIT Test appears acceptable to determine latent TBC before biological agent use. Consequently, the QFT-GIT Test can be appropriately used in BCG-vaccinated countries.tr_TR
dc.language.isoentr_TR
dc.publisherClinical Rheumatologytr_TR
dc.relation.isversionof10.1007/s10067-020-05443-3tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.subjectTuberculin skin test (TST)tr_TR
dc.subject(QFT-GIT) testtr_TR
dc.subjectQuantiFERON®-TB Gold In-Tubetr_TR
dc.subjectLatent tuberculosistr_TR
dc.subjectAnti-TNF-α drugstr_TR
dc.subjectBCGtr_TR
dc.subject.lcshTıp uygulamasıtr_TR
dc.titleQuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life resultstr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalClinical Rheumatologytr_TR
dc.contributor.departmentİç Hastalıklarıtr_TR
dc.identifier.volumeEpub ahead of printtr_TR
dc.description.indexPubMedtr_TR
dc.fundingYoktr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess